•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

S02682 Summary:

BILL NOS02682
 
SAME ASSAME AS A00582
 
SPONSORBRESLIN
 
COSPNSRHOYLMAN-SIGAL, SKOUFIS
 
MLTSPNSR
 
Amd §4902, Ins L; amd §4902, Pub Health L
 
Ensures that step therapy shall not apply to medically necessary prescription drugs in the dermatologic, hematology, ophthalmologic, rheumatic, gastrointestinal, neurology, and oncology therapeutic classes, including non-formulary drugs.
Go to top

S02682 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          2682
 
                               2023-2024 Regular Sessions
 
                    IN SENATE
 
                                    January 24, 2023
                                       ___________
 
        Introduced  by  Sen. BRESLIN -- read twice and ordered printed, and when
          printed to be committed to the Committee on Insurance
 
        AN ACT to amend the insurance law and the public health law, in relation
          to protecting certain therapeutic classes from step therapy
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1.    Subsection  (a) of section 4902 of the insurance law is
     2  amended by adding a new paragraph 14 to read as follows:
     3    (14) When establishing a step therapy protocol, a  utilization  review
     4  agent  shall  ensure  that  such  protocol  shall not apply to medically
     5  necessary prescription drugs in the dermatologic, hematology, ophthalmo-
     6  logic, rheumatic, gastrointestinal, neurology, and oncology  therapeutic
     7  classes, including non-formulary drugs.
     8    §  2. Section 4902 of the public health law is amended by adding a new
     9  subdivision 5 to read as follows:
    10    5. When establishing a step therapy  protocol,  a  utilization  review
    11  agent  shall  ensure  that  such  protocol  shall not apply to medically
    12  necessary prescription drugs in the dermatologic, hematology, ophthalmo-
    13  logic, rheumatic, gastrointestinal, neurology, and oncology  therapeutic
    14  classes, including non-formulary drugs.
    15    § 3. This act shall take effect immediately.
 
 
 
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD02499-01-3
Go to top